The discovery did not begin with a hypothesis about any particular bacterium. Instead, the researchers built AURORA, a generative artificial intelligence framework that integrates multiple data modalities, including metagenomic sequences, plasma metabolomics, gene expression and physiological measurements, into a unified model of human aging. Within this framework, the team constructed multi-modality aging clocks, statistical models that estimate a person’s biological age from molecular and phenotypic features, and then used the model to perform in silico screening: systematically simulating thousands of potential interventions to identify which changes would most effectively reduce the gap between predicted biological age and chronological age.

That computational screen produced an unexpected front-runner. When the abundance of Neisseria flavescens was virtually increased in the model, the predicted age gap shifted in a favorable direction, and the simulated perturbation also produced beneficial changes in physiological signatures, promoted the abundance of known health-associated gut taxa and enhanced the biosynthesis of metabolites with documented benefits. In a natural human aging cohort, individuals classified as slow agers, whose biological clocks ran younger than their chronological years, carried significantly more of this oral species than fast agers. The association was replicated in longitudinal data tracking one-year changes in bacterial abundance against changes in the aging measure.

To move beyond correlation, the team isolated two live strains of N. flavescens, designated a11 and e5, from human donors and sequenced their genomes, which have been deposited under the accessions GWHHOEZ01000000 and GWHHOEA01000000. Laboratory analysis confirmed that both strains actively produce vitamins and other beneficial metabolites predicted by the computational framework. Targeted mass spectrometry of bacterial culture supernatants verified the metabolic output, providing a mechanistic bridge between the human association data and the biological activity of the organism itself.

The first functional test took place in Caenorhabditis elegans, the transparent roundworm that has long served as a workhorse of aging research. When worms were fed live N. flavescens instead of their standard laboratory diet of Escherichia coli OP50, their lifespans lengthened and their healthspans, the portion of life spent in good condition, improved. Supplementation also attenuated the age-related decline in mobility during early adulthood and altered body size, with independent replication experiments confirming the lifespan extension for both strains. Heat-killed bacteria likewise preserved worm mobility, hinting that structural components of the microbe, rather than only its living metabolic activity, may contribute to the effect.

In aged mice, the researchers turned to heat-killed N. flavescens, a form of supplementation that avoids the safety considerations of administering a live organism. After ten weeks of treatment, the animals’ serum metabolome, liver transcriptome and gut microbiome all shifted measurably toward younger profiles. Principal-component analyses showed that the metabolic and transcriptional states of treated twenty-month-old mice moved closer to those of young two-month-old controls, and regression analysis demonstrated that treatment-associated fold changes across metabolites, microbial species, microbial pathways and liver transcripts tended to oppose the changes normally driven by aging itself. The effect was partial rather than a wholesale reversal, but the consistent directional rescue across three distinct molecular layers is striking.

The study also addressed how an oral bacterium could plausibly influence systemic aging. Paired analyses of oral and gut microbiome data, including paired samples from the Human Microbiome Project, revealed links between N. flavescens abundance and the composition of the gut ecosystem, including associations with Akkermansia muciniphila, a gut bacterium widely studied for its beneficial effects on metabolic health and barrier function. Predicted downstream effects included changes in immune signaling pathways in peripheral blood mononuclear cells, suggesting a route by which oral microbial signals propagate through host metabolism and immunity rather than acting locally in the mouth alone.

Technically, the work represents a notable advance in how candidate interventions are identified. Traditional microbiome-aging studies typically search for correlations between individual taxa and chronological age or survival, an approach that the authors note would not have singled out N. flavescens as a top hit in their own data. By instead simulating perturbations within a generative model trained on multi-omics data, AURORA can prioritize organisms whose expansion is predicted to shift the entire aging state favorably, a logic closer to a causal intervention than a population association. The framework and all analysis code are freely available, and the underlying sequencing datasets have been deposited in public repositories under BioProject PRJCA057750 and associated accessions.

Important caveats remain. The human evidence is associative, the mouse experiments used heat-killed preparations whose active components have not yet been identified, and no human intervention trial has been conducted. A patent covering N. flavescens and its applications is pending, filed by two of the authors, which signals commercial interest but also that translational development is still at an early stage. Even so, the convergence of computational prediction, human cohort data, worm lifespan experiments and mouse molecular rescue makes a compelling case that the mouth, a microbiome site routinely dismissed as merely a gateway to dental disease, deserves far more attention in geroscience. If the findings hold up in further studies, the next geroprotective intervention might not come from a laboratory-synthesized molecule but from a common commensal already living between our teeth.

Subject of Research: Identification of the oral commensal Neisseria flavescens as a geroprotective microbe linked to decelerated human aging

Article Title: Multi-modality profiling identifies Neisseria flavescens as a central geroprotective oral commensal in humans

Article References: Chen, J., Ren, Y., Zhou, Y., Wang, Z., Li, J., Guo, X., Xu, H., Wang, Y., Tang, H., & Han, J.-D. J. (2026). Multi-modality profiling identifies Neisseria flavescens as a central geroprotective oral commensal in humans. Nature Aging. https://doi.org/10.1038/s43587-026-01220-0

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01220-0

Keywords: aging, oral microbiome, Neisseria flavescens, AURORA, geroprotection, aging clocks, multi-omics, Caenorhabditis elegans, gut microbiome, probiotics, longevity, metabolomics

Immunosenescence is far more than a simple decline in immune vigor. It is a sweeping remodeling of both the innate and adaptive arms of immunity, marked by a shrinking pool of naive T cells, an accumulation of exhausted memory cells, a narrowing of T-cell receptor diversity, and a chronic, low-grade inflammatory state often called inflammaging. These changes are closely tied to impaired immunometabolism, mitochondrial dysfunction, and shifts in key signaling networks, including the AMPK/mTOR axis, the NF-kappaB pathway, autophagy, and the NLRP3 inflammasome. Because no single molecular defect drives the process, the authors contend that a multi-target agent may be better suited to intervene than highly specific drugs aimed at one pathway at a time.

Berberine, an isoquinoline alkaloid extracted from plants such as Berberis vulgaris, has been used in traditional Chinese and Ayurvedic medicine for centuries. Modern pharmacology has mapped an impressive array of its molecular actions: it activates AMP-activated protein kinase (AMPK) partly by inhibiting mitochondrial respiratory complex I, suppresses mTOR signaling, modulates NF-kappaB-driven inflammation, promotes autophagy, and inhibits NLRP3 inflammasome activation. Each of these targets sits squarely at the intersection of the pathways that go awry during immunosenescence. Clinical evidence already supports berberine’s benefits in cardiometabolic disease, including type 2 diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, and a phase 2 trial of berberine ursodeoxycholate showed proof of concept in patients with non-alcoholic steatohepatitis and type 2 diabetes.

The review assembles evidence from cellular, animal, and early human studies that speaks directly to immune aging. In cell culture, berberine suppresses gero-conversion, the transition from reversible cell-cycle arrest to full senescence, and protects cells from oxidative stress-induced senescence through AMPK activation, restoration of autophagic flux, and elevation of intracellular NAD+. In mice, the compound ameliorates cellular senescence and extends lifespan by regulating p16 and cyclin protein expression. In simpler organisms, berberine prolongs lifespan and stimulates locomotor activity in Drosophila melanogaster and extends lifespan in Caenorhabditis elegans through multi-target antioxidant effects and ROS-dependent activation of the PMK-1/SKN-1 stress-response pathway.

Particularly relevant to immune aging are berberine’s documented effects on inflammatory signaling. The compound inhibits LPS-induced inflammatory responses through the NF-kappaB pathway, blocks NLRP3 inflammasome activation in macrophages by triggering autophagy and regulating the mTOR/mitochondrial ROS axis, and reduces SASP-related inflammation through the RXRalpha/PPARgamma/NEDD4 pathway in models of atherosclerosis. It also modulates sirtuin 1 activity, a deacetylase implicated in immune cell longevity, and enhances innate antiviral defenses via the p38 MAPK pathway, with demonstrated anti-influenza activity in mice. Because the senescence-associated secretory phenotype, or SASP, is a major driver of chronic age-related inflammation, a drug that dampens SASP output while simultaneously supporting autophagy and mitochondrial quality control addresses several hallmarks of immune aging at once.

The review also highlights a newer generation of berberine derivatives engineered to overcome the parent compound’s most stubborn limitation: poor oral bioavailability. Berberine is poorly absorbed from the gut, relies partly on gut microbiota transformation into the intestine-absorbable form dihydroberberine, and is subject to efflux by P-glycoprotein. Chemists have responded with 8,8-dimethyldihydroberberine, 9-O-substituted and 9-N-alkyl derivatives, liposomal and nanoparticle formulations, and self-microemulsifying delivery systems, all of which improve absorption in animal or human studies. Some derivatives add entirely new capabilities: a 13-decyl berberine derivative has been described as a novel mitochondria-targeted antioxidant and potent inhibitor of ferroptosis, while tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy, and berberrubine-based mitorubin compounds improve mitochondrial function and protect against age-related cardiac dysfunction.

Yet the authors are careful to temper enthusiasm with critical caveats. Much of the immunosenescence-relevant evidence comes from in vitro work or from animal models whose immune systems differ substantially from aged humans. Direct clinical trials testing berberine specifically against immunosenescence biomarkers, such as T-cell receptor repertoire diversity, p16INK4a expression in peripheral blood T cells, senescence-associated beta-galactosidase in CD8+ T cells, or inflammatory aging clocks like iAge, have not been performed. Safety considerations also warrant attention: berberine inhibits cytochrome P450 enzymes in humans, raising drug-interaction risks, and it has been shown to alter blood levels of immunosuppressants such as cyclosporin A in transplant recipients. Its interaction with the adenine nucleotide translocator and complex I inhibition, while mechanistically central to AMPK activation, could be a double-edged sword in metabolically stressed immune cells.

To move the field forward, the review proposes a framework for future studies. The authors call for properly designed experiments in aged animal models that measure established immunosenescence biomarkers rather than generic inflammation endpoints, followed by carefully monitored human trials in older populations. They emphasize the value of modern immune-aging metrics, including single-cell immune aging clocks that capture inter-individual heterogeneity during infection and vaccination, and suggest that derivatives with improved bioavailability and mitochondrial targeting should be prioritized. Vaccine responsiveness in the elderly, which is notoriously blunted and linked to T-cell autophagy decline, is identified as a clinically meaningful outcome that a berberine-based intervention could plausibly improve.

The broader significance of the analysis lies in its reframing of an old herbal medicine as a systems-level geroprotector. Where most anti-aging pharmacology pursues single targets, berberine’s pleiotropy, acting simultaneously on energy sensing, inflammatory transcription, autophagy, inflammasome activity, and mitochondrial function, mirrors the interconnected nature of immune aging itself. Whether that pleiotropy translates into safe and measurable rejuvenation of the human immune system remains an open question, but the review provides the mechanistic rationale and the experimental roadmap needed to find out. If subsequent trials validate the promise, a compound once confined to traditional apothecaries could become a cornerstone of interventions designed to keep aging immune systems, and the aging populations they protect, healthier for longer.

Subject of Research: Evaluation of berberine and its derivatives as multi-target modulators of age-related immune system decline (immunosenescence).

Article Title: Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation

Article References: Zinovkin, R. A., Lyamzaev, K. G., Churov, A., Maltseva, O., & Wu, Z. (2026). Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation. Biogerontology, 27(5), Article 153. https://doi.org/10.1007/s10522-026-10504-2

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10504-2

Keywords: berberine, immunosenescence, aging, AMPK, mTOR, NF-kappaB, autophagy, NLRP3 inflammasome, inflammaging, mitochondria, berberine derivatives, geroprotection

The logic behind the approach rests on a decade of progress in proteomics, the large-scale study of the protein complement of biological systems. Unlike the genome, which is essentially fixed at conception, the proteome is dynamic: it shifts with infection, stress, exercise, disease, and, crucially, with age itself. Researchers have shown that machine-learning models trained on thousands of plasma protein measurements can predict chronological age with remarkable accuracy, and that the difference between predicted and actual age—sometimes called proteomic age acceleration—correlates with frailty, multimorbidity, and mortality risk. These proteomic clocks are conceptually analogous to the epigenetic clocks based on DNA methylation that transformed aging research in the 2010s, but they offer distinct advantages for interventional trials: blood proteins are readily sampled repeatedly, they respond to physiological change on shorter timescales than DNA methylation marks, and many of the proteins involved are themselves drug targets or biomarkers already familiar to the pharmaceutical industry.

What the new study demonstrates is that this technology can survive contact with the realities of clinical trial design. The researchers integrated multiple proteomic aging clocks into the analytical framework of a phase 2a trial, the earliest stage at which a therapeutic candidate is tested in patients or at-risk volunteers to gather preliminary evidence of biological activity. Rather than treating biological age estimation as an exploratory afterthought, the team built the clocks into the statistical evaluation plan from the outset, defining in advance how changes in proteomic age would be measured, how measurement noise would be handled, and how multiple clock outputs could be combined to give a coherent picture of whether an intervention was shifting the biology of aging in a favorable direction.

The emphasis on simultaneous assessment is the study’s most distinctive contribution. Different aging clocks, trained on different protein sets and different cohorts, capture partly overlapping and partly distinct facets of the aging process—one model may be more sensitive to inflammatory pathways, another to metabolic or hepatic changes, a third to renal or cardiovascular decline. By deploying a suite of clocks in parallel rather than betting on a single algorithm, the trial design allows investigators to ask not merely whether an intervention changes a number, but whether it changes the underlying biology in a way that is consistent across independent measures of aging. Convergence across multiple clocks provides a form of internal replication that a single biomarker cannot offer, while divergence among clocks can itself be informative, pointing to organ-specific or pathway-specific effects that would otherwise be invisible.

Technically, the integration demanded solutions to several stubborn problems. Proteomic measurements are sensitive to pre-analytical variables: the choice of assay platform, the timing of blood draws, fasting status, and even the season of sample collection can shift protein concentrations. Longitudinal interpretation requires that the analytical pipeline distinguish true within-person change from batch effects and ordinary biological fluctuation. The study addressed these challenges by anchoring the clocks to repeated baseline sampling, applying rigorous quality control to the proteomic data, and using statistical models that estimate change within individuals rather than relying solely on comparisons between treatment and control groups at a single time point. This within-person framing is essential for short trials, because it dramatically increases statistical power when each participant serves as their own reference for the direction and magnitude of biological aging.

The broader significance of the work lies in what it could do to the economics of geroscience. Developing drugs that target aging has long been caught in a regulatory and commercial Catch-22: regulators generally approve treatments for diseases, not for aging itself, because aging lacks an agreed clinical endpoint; without approved indications, investment in geroprotective therapies has lagged. Biomarkers that can credibly demonstrate a slowing of biological aging over months rather than decades offer a path through this impasse. If proteomic clocks can be validated as surrogate endpoints or at least as robust pharmacodynamic markers, early-phase trials of candidate geroprotectors—whether repurposed drugs such as rapamycin and its analogues, senolytic agents that clear senescent cells, or novel molecules designed around aging pathways—become faster, smaller, and far cheaper to run.

The phase 2a setting is precisely where such markers earn their keep. Phase 2a studies are designed to detect signals of biological activity, not to prove clinical benefit, and a biomarker that reliably responds to an intervention’s mechanism of action is exactly the kind of signal these trials exist to find. Embedding proteomic clocks at this stage creates a screening funnel: interventions that show consistent effects across multiple aging measures can be advanced to larger trials with confidence, while those that leave the proteome untouched can be deprioritized before expensive late-stage development. In effect, the clocks function as a biological readout of geroprotection, analogous to how viral load measurements transformed the early development of antiretroviral therapies.

Important caveats remain, and the authors and the field are careful to acknowledge them. A change in a proteomic aging clock is not yet proof that a therapy extends healthspan or lifespan; the clocks are validated against age-related outcomes in observational data, and demonstrating that an intervention moves the biomarker is only the first step toward showing that it changes disease trajectories. Calibration across diverse populations is another open question, since proteomic aging signatures can vary with ancestry, sex, socioeconomic factors, and baseline health status, and a clock optimized in one cohort may miscalibrate in another. Standardization across assay platforms and laboratories will also be necessary before proteomic age becomes a measure that regulators and clinicians can compare across studies. The new work does not resolve these issues single-handedly, but it establishes a concrete, tested framework within which they can be addressed trial by trial.

Even so, the moment feels like an inflection point. The geroscience field has spent years generating compelling animal data on interventions that delay aging, only to face a translational bottleneck at the human frontier. The integration of proteomic aging clocks into a real phase 2a clinical trial shows that the measurement problem—long the field’s most fundamental limitation—is tractable with current technology. If subsequent trials replicate and extend this framework, the result could be a virtuous cycle in which better biomarkers enable faster trials, faster trials attract greater investment, and greater investment produces the interventions that finally move the needle on human healthspan. Aging, for the first time, is being measured in the clinic on the timescale of a clinical trial, and that change may prove as important as any single therapeutic candidate now in development.

Subject of Research: Proteomic aging clocks integrated into a phase 2a clinical trial for geroprotective assessment

Article Title: Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment

Article References: Zhavoronkov, A., Galkin, F., Chen, S., Ren, F., Aliper, A., Durymanov, M., Sidorenko, D., Cui, H., Han, J.-D. J., Xu, H., Liu, X., Xu, Z., Kuppe, C., Austin Argentieri, M., Ying, K., Goeminne, L. J. E., Moqri, M., Tyshkovskiy, A., & Gladyshev, V. N. (2026). Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03286-y

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03286-y

Keywords: proteomic aging clocks, biological age, geroprotection, phase 2a trial, geroscience, biomarkers, plasma proteomics, aging interventions, healthspan, clinical trial design, machine learning, surrogate endpoints